Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture.

Chen S, Giannakou A, Wyman S, Gruzas J, Golas J, Zhong W, Loreth C, Sridharan L, Yamin TT, Damelin M, Geles KG.

Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11671-E11680. doi: 10.1073/pnas.1803718115. Epub 2018 Nov 28.

2.

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.

Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M, Hampl J, Lazetic S, Pulito V, Rosfjord E, Sun Y, King L, Barletta F, Betts A, Guffroy M, Falahatpisheh H, O'Donnell CJ, Stull R, Pysz M, Escarpe P, Liu D, Foord O, Gerber HP, Sapra P, Dylla SJ.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaag2611. doi: 10.1126/scitranslmed.aag2611.

PMID:
28077676
3.

Upregulation of RNA Processing Factors in Poorly Differentiated Lung Cancer Cells.

Geles KG, Zhong W, O'Brien SK, Baxter M, Loreth C, Pallares D, Damelin M.

Transl Oncol. 2016 Apr;9(2):89-98. doi: 10.1016/j.tranon.2016.01.006. Epub 2016 Mar 4.

4.

Breast cancer cells respond differentially to modulation of TGFβ2 signaling after exposure to chemotherapy or hypoxia.

O'Brien SK, Chen L, Zhong W, Armellino D, Yu J, Loreth C, Follettie M, Damelin M.

Cancer Res. 2015 Nov 1;75(21):4605-16. doi: 10.1158/0008-5472.CAN-15-0650. Epub 2015 Sep 4.

5.

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.

Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, Aujay M, Fong S, Khandke K, Pulito V, Ernstoff E, Escarpe P, Bernstein J, Pysz M, Zhong W, Upeslacis E, Lucas J, Lucas J, Nichols T, Loving K, Foord O, Hampl J, Stull R, Barletta F, Falahatpisheh H, Sapra P, Gerber HP, Dylla SJ.

Clin Cancer Res. 2015 Sep 15;21(18):4165-73. doi: 10.1158/1078-0432.CCR-15-0695. Epub 2015 May 26.

6.

Evolving Strategies for Target Selection for Antibody-Drug Conjugates.

Damelin M, Zhong W, Myers J, Sapra P.

Pharm Res. 2015 Nov;32(11):3494-507. doi: 10.1007/s11095-015-1624-3. Epub 2015 Jan 15.

PMID:
25585957
7.

Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug Conjugate.

Hu G, Leal M, Lin Q, Affolter T, Sapra P, Bates B, Damelin M.

Mol Pharm. 2015 Jun 1;12(6):1730-7. doi: 10.1021/mp5006323. Epub 2014 Dec 9.

PMID:
25423493
8.

Comprehensive interrogation of a minimalist synthetic CDR-H3 library and its ability to generate antibodies with therapeutic potential.

Mahon CM, Lambert MA, Glanville J, Wade JM, Fennell BJ, Krebs MR, Armellino D, Yang S, Liu X, O'Sullivan CM, Autin B, Oficjalska K, Bloom L, Paulsen J, Gill D, Damelin M, Cunningham O, Finlay WJ.

J Mol Biol. 2013 May 27;425(10):1712-30. doi: 10.1016/j.jmb.2013.02.015. Epub 2013 Feb 19.

PMID:
23429058
9.

Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.

Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, Dougher M, Narayanan B, Giannakou A, Khandke K, Dushin R, Ernstoff E, Lucas J, Leal M, Hu G, O'Donnell CJ, Tchistiakova L, Abraham RT, Gerber HP.

Mol Cancer Ther. 2013 Jan;12(1):38-47. doi: 10.1158/1535-7163.MCT-12-0603. Epub 2012 Dec 5.

10.

Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells.

Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, DiJoseph JF, Karnoub M, Huang S, Diesl V, Behrens C, Choe SE, Rios C, Gruzas J, Sridharan L, Dougher M, Kunz A, Hamann PR, Evans D, Armellino D, Khandke K, Marquette K, Tchistiakova L, Boghaert ER, Abraham RT, Wistuba II, Zhou BB.

Cancer Res. 2011 Jun 15;71(12):4236-46. doi: 10.1158/0008-5472.CAN-10-3919. Epub 2011 May 3.

11.

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery.

Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB.

Nat Rev Drug Discov. 2009 Oct;8(10):806-23. doi: 10.1038/nrd2137. Review.

PMID:
19794444
12.

Hyperconserved CpG domains underlie Polycomb-binding sites.

Tanay A, O'Donnell AH, Damelin M, Bestor TH.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5521-6. Epub 2007 Mar 21.

13.

Biological functions of DNA methyltransferase 1 require its methyltransferase activity.

Damelin M, Bestor TH.

Mol Cell Biol. 2007 Jun;27(11):3891-9. Epub 2007 Mar 19.

14.

The decatenation checkpoint.

Damelin M, Bestor TH.

Br J Cancer. 2007 Jan 29;96(2):201-5. Epub 2007 Jan 9. Review.

15.

Decatenation checkpoint deficiency destabilizes the stem cell genome.

Damelin M, Bestor TH.

Cell Cycle. 2006 Feb;5(4):345-6. Epub 2006 Feb 15. No abstract available.

PMID:
16479155
16.

Combing over heritable gene silencing.

Damelin M, Ooi SK, Bestor TH.

Nat Struct Mol Biol. 2006 Feb;13(2):100-1. No abstract available.

PMID:
16462811
17.

Analysis of Protein Interactions In Vivo with Fluorescence Resonance Energy Transfer (FRET).

Damelin M, Silver P.

CSH Protoc. 2006 Oct 1;2006(5). pii: pdb.prot4581. doi: 10.1101/pdb.prot4581.

PMID:
22485962
18.

An Explanation of Symbols Used for Analysis of FRET Data.

Damelin M, Silver P.

CSH Protoc. 2006 Oct 1;2006(5). pii: pdb.ip9. doi: 10.1101/pdb.ip9. No abstract available.

PMID:
22485937
19.

Equipment for In Vivo FRET Analysis.

Damelin M, Silver P.

CSH Protoc. 2006 Oct 1;2006(5). pii: pdb.ip8. doi: 10.1101/pdb.ip8. No abstract available.

PMID:
22485936
20.

Experimental Design for In Vivo FRET Analysis.

Damelin M, Silver P.

CSH Protoc. 2006 Oct 1;2006(5). pii: pdb.ip10. doi: 10.1101/pdb.ip10. No abstract available.

PMID:
22485930
21.

Decatenation checkpoint deficiency in stem and progenitor cells.

Damelin M, Sun YE, Sodja VB, Bestor TH.

Cancer Cell. 2005 Dec;8(6):479-84.

22.
23.

Nuclear protein transport.

Damelin M, Silver PA, Corbett AH.

Methods Enzymol. 2002;351:587-607. Review. No abstract available.

PMID:
12073370
24.

The genome-wide localization of Rsc9, a component of the RSC chromatin-remodeling complex, changes in response to stress.

Damelin M, Simon I, Moy TI, Wilson B, Komili S, Tempst P, Roth FP, Young RA, Cairns BR, Silver PA.

Mol Cell. 2002 Mar;9(3):563-73.

26.

Interactions between a nuclear transporter and a subset of nuclear pore complex proteins depend on Ran GTPase.

Seedorf M, Damelin M, Kahana J, Taura T, Silver PA.

Mol Cell Biol. 1999 Feb;19(2):1547-57.

Supplemental Content

Loading ...
Support Center